313 related articles for article (PubMed ID: 34570179)
1. Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.
Stengel A; Baer C; Walter W; Meggendorfer M; Kern W; Haferlach T; Haferlach C
Blood Adv; 2021 Nov; 5(21):4426-4434. PubMed ID: 34570179
[TBL] [Abstract][Full Text] [Related]
2. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM; Lasho TL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
[TBL] [Abstract][Full Text] [Related]
3. Clonal cytopenias of undetermined significance: potential predictor of myeloid malignancies?
Vobugari N; Heuston C; Lai C
Clin Adv Hematol Oncol; 2022 Jun; 20(6):375-383. PubMed ID: 35731608
[TBL] [Abstract][Full Text] [Related]
4. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.
Szuber N; Orazi A; Tefferi A
Am J Hematol; 2024 Apr; ():. PubMed ID: 38644693
[TBL] [Abstract][Full Text] [Related]
5. [Pathophysiology of hematological malignancies associated with ASXL1 mutations].
Fujino T
Rinsho Ketsueki; 2022; 63(6):561-572. PubMed ID: 35831189
[TBL] [Abstract][Full Text] [Related]
6. Myeloid malignancies: mutations, models and management.
Murati A; Brecqueville M; Devillier R; Mozziconacci MJ; Gelsi-Boyer V; Birnbaum D
BMC Cancer; 2012 Jul; 12():304. PubMed ID: 22823977
[TBL] [Abstract][Full Text] [Related]
7. A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1-negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia-related.
Chen D; Geyer J; Bagg A; Hasserjian R; Weinberg OK
Int J Lab Hematol; 2024 Apr; ():. PubMed ID: 38665121
[TBL] [Abstract][Full Text] [Related]
8. [TFH lymphoma and associated clonal hematopoiesis].
Nann D; Fend F; Quintanilla-Martinez L
Pathologie (Heidelb); 2023 Dec; 44(Suppl 3):144-149. PubMed ID: 37870568
[TBL] [Abstract][Full Text] [Related]
9. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
[TBL] [Abstract][Full Text] [Related]
10. Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Karantanos T; Gondek LP; Varadhan R; Moliterno AR; DeZern AE; Jones RJ; Jain T
Br J Haematol; 2021 Jun; 193(6):1142-1150. PubMed ID: 34028801
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
Liu YC; Illar GM; Bailey NG
J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
[TBL] [Abstract][Full Text] [Related]
12. [Genomic aberrations in myelodysplastic syndromes and related disorders].
Makishima H
Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
[TBL] [Abstract][Full Text] [Related]
13. Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms: A Report of the Association for Molecular Pathology.
McClure RF; Ewalt MD; Crow J; Temple-Smolkin RL; Pullambhatla M; Sargent R; Kim AS
J Mol Diagn; 2018 Nov; 20(6):717-737. PubMed ID: 30138727
[TBL] [Abstract][Full Text] [Related]
14. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
15. ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia.
Shuai W; Zuo Z; Li N; Garces S; Jelloul FZ; Ok CY; Li S; Xu J; You MJ; Wang W; Rehder C; Jabbour EJ; Patel KP; Medeiros LJ; Yin CC
Cancer; 2023 Mar; 129(6):878-889. PubMed ID: 36583229
[TBL] [Abstract][Full Text] [Related]
16. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
[TBL] [Abstract][Full Text] [Related]
17. Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy.
Gill H; Leung AY; Kwong YL
Int J Mol Sci; 2016 Mar; 17(4):440. PubMed ID: 27023522
[TBL] [Abstract][Full Text] [Related]
18. Association of Somatic Gene Mutations with Risk of Transformation into Acute Myeloid Leukemia in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis.
Sutandyo N; Mulyasari R; Kosasih A; Rinaldi I; Louisa M; Kevinsyah AP; Winston K
Asian Pac J Cancer Prev; 2022 Apr; 23(4):1107-1116. PubMed ID: 35485665
[TBL] [Abstract][Full Text] [Related]
19. [Predisposition and progression of myelodysplastic syndromes].
Makishima H
Rinsho Ketsueki; 2021; 62(4):278-288. PubMed ID: 33967153
[TBL] [Abstract][Full Text] [Related]
20. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
Thol F; Kade S; Schlarmann C; Löffeld P; Morgan M; Krauter J; Wlodarski MW; Kölking B; Wichmann M; Görlich K; Göhring G; Bug G; Ottmann O; Niemeyer CM; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
Blood; 2012 Apr; 119(15):3578-84. PubMed ID: 22389253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
